

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. **P50438-1C2**
First Named Inventor **Blackburn, et al.**

(For new nonprovisional applications under 37 CFR 1.53(b))

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER **EV 332 944 075 US** DATE OF DEPOSIT: **07 October 2003**

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:

COMMISSIONER FOR PATENTS, MAIL STOP: PATENT APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

NAME OF PERSON MAILING PAPER OR FEE
(TYPE OR PRINT)

Emma Dennis

SIGNATURE

Emma Dennis

17302 U.S.PTO
10/681421

100703

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570
 - ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))
(Submit an original, and a duplicate for fee processing)
2. ☒ The total fee is calculated as shown below:

| | |
|--|-----------------|
| Basic Filing fee | \$770.00 |
| Total Claims 20 - 20 = 0 x \$18 | \$ 0.00 |
| Independent Claims 3 - 3 = 0 x \$84 | \$ 0.00 |
| <input type="checkbox"/> Multiple Dependent Claim present. \$280 | |
| TOTAL FILING FEE | \$770.00 |

☐ Cancel in this application original claims _to _ of the prior application before calculating the filing fee.

☒ Charge **\$770.00** to the above indicated Deposit Account.
- 3a. ☒ Specification excluding Drawings [Total Pages] 140
- 3b. ☒ Abstract on a separate sheet [Total Pages] 1
4. ☒ Drawing(s) (35 USC 113) [Total Sheets] 14
5. ☒ Declaration and Power of Attorney [Total Pages] 3
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17a completed)
 - c. ☐ Unsigned Declaration
[Note Box 6 below]
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

7. ☒ The Title of the Invention:
Antithrombotic Agents
8. ☒ Nucleotide and/or Amino Acid Sequence Submission
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies
 - d. ☒ Use the identical computer-readable form filed in Application No. 09/965,099, filed 26 September 2001 as the computer-readable form for the instant application. (37 CFR 1.821(e))

ACCOMPANYING APPLICATION PARTS

9.
 - a. ☐ Information Disclosure Statement (IDS)
 - b. ☐ PTO-1449
 - c. ☐ Copies of all IDS Citations
10. ☐ Assignment Papers (cover sheet & document(s))
11. ☒ Prior Application is Assigned to:
SmithKline Beecham Corporation
(for continuation/divisional with Box 17a completed)
12. ☒ Preliminary Amendment [Total Pages] 3
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. ☒ Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/965,099 filed 26 September 2001. A PTO-1449 listing the references is enclosed.
16. ☒ Other: Copy of Request for Three Month Extension of Time filed in 09/965,099; copy of Response and Property Rights Statement executed by the Head of Thrombotic Research and filed in 09/965,099; copy of Response and Property Rights Statements signed by inventors Blackburn and Fuerstein and filed in 09/965,099.

6. ☒ Incorporation By Reference (useable if Box 5b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

17. ☒ Priority Information, check appropriate box and supply the requisite information

a. The accompanying application is a ☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)
of prior application No: 09/965,099, filed 26 September 2001.

b. ☐ Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications:
Application No. _____ filed _____

c. ☒ Add claim to priority via Preliminary Amendment.

Correspondence
Address:

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939

Telephone

(610) 270-5968 Fax (610) 270-5090

Signature
Name

Respectfully Submitted,

William R. Majarian
William R. Majarian

Registration
No.

41,173

20462

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: COMMISSIONER FOR PATENTS, MAIL STOP
RESPONSE TO OFFICE ACTIONS, P.O. BOX 1450, ALEXANDRIA, VA
22313-1450, ON 07 OCTOBER 2003

Delia A. Pishchik
NAME OF PERSON MAILING DOCUMENT

10/7/03
DATE

Attorney Docket No. P50438-1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|-------------|--------------------------|------------------------------|
| Applicant: | Blackburn, <i>et al.</i> | 07 October 2003 |
| Serial No.: | 09/965,099 | Group Art Unit No.: 1645 |
| Filed: | 26 September 2001 | Examiner: Patricia Ann Duffy |
| For: | Antithrombotic Agents | |

TRANSMITTAL LETTER

Enclosed is a Request for Three Month Extension of Time in response to the Office Action dated 09 April 2003. A Continuation Application was filed under separate cover on 07 October 2003, and sent by Express Mail.

EXTENSION OF TIME PETITION

Applicants hereby petition for an extension of time for response from the date of the Examiner's action as needed, the fee being as follows:

| | | |
|-----|---|--------|
| () | one month extension..... | \$ 110 |
| () | two months extension..... | \$ 410 |
| (X) | three months extension..... | \$ 930 |
| () | four months extension | |
| | (not beyond statutory time period)..... | \$1450 |
| () | five months extension | \$1970 |

Charge \$930.00 to Deposit Account No. 19-2570. Two copies of this form are enclosed.

Please charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to Deposit Account No. 19-2570. Also, should the Patent and Trademark Office determine that the fee calculated in the above extension petition is not deemed sufficient to have this response considered as being timely filed, this constitutes a petition for extension of time for the minimum period to effect timely filing, and the Commissioner is authorized to debit any necessary fee to said deposit account.

Respectfully submitted,

William R. Majarian
William R. Majarian
Attorney for Applicants
Registration No. 41,173

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968 Fax (610) 270-5090

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EV 332 944 075 US
DATE OF DEPOSIT 07 October 2003

Attorney Docket No.: P50438-1C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|-------------|--------------------------|-----------------------------|
| Applicant: | Blackburn, <i>et al.</i> | 07 October 2003 |
| Serial No.: | To Be Assigned | Group Art Unit No.: Unknown |
| Filed: | Herewith | Examiner: Unknown |
| For: | Antithrombotic Agents | |

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**


Commissioner for Patents
Mail Stop: Patent Application
P.O. Box 1450
Alexandria, Va 22313-1450

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and **(e)**, respectively, are the same.
- (X) I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)** does not include new matter.
- () I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**, included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.

Serial No.: To Be Assigned
Group Art Unit No.: Unknown

- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, is identical to that originally filed.

Respectfully submitted,



William R. Majarian
Attorney for Applicants
Registration No. 41,173

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968
Facsimile (610) 270-5090
N:\Will\APPS\P-cases\P50438\P50438-1C2\statsupp.doc